Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and molecular features, including targetable mutations in several kinases such as BRAF or c-KIT. The successful development of therapies targeting these mutations has resulted in new specific treatment o...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Elsevier
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041182/ |